Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Authors
Keywords
Dipeptidyl peptidase-4 inhibitor, Glucagon-like peptide-1 receptor agonist, Non-alcoholic fatty liver disease, Type 2 diabetes
Journal
DIABETOLOGIA
Volume 59, Issue 12, Pages 2588-2593
Publisher
Springer Nature
Online
2016-09-15
DOI
10.1007/s00125-016-4100-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- GLP-1 based therapies: clinical implications for gastroenterologists
- (2016) Mark M Smits et al. GUT
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice
- (2016) Parambir S. Dulai et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
- (2015) Niraj S. Patel et al. Clinical Gastroenterology and Hepatology
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
- (2015) Aijaz Ahmed et al. Clinical Gastroenterology and Hepatology
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
- (2015) Hiroyuki Kato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
- (2015) Mark M Smits et al. BMJ Open
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
- (2012) Donghee Kim et al. HEPATOLOGY
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now